Results from three independent discovery campaigns show Optimers with up to 142x higher affinity for more sensitive assays. The three main reasons people explore Optimer development are: There is no…
Affinity binders are the workhorses of assays and methods across the life sciences. From biologics to bioprocessing ligands and research reagents, the requirements for affinity binders vary according to…
Your research is unique. We tailor your Optimer discovery strategy to match, delivering the highest chance of success and the best Optimer performance. Download this booklet to learn how: …
Finding the right affinity ligand pair is a bottleneck in immunoassay development where the Optimer platform can help. Whether you need an additional reagent to form an aptamer-antibody pair or…
Not all protein-binding aptamers are developed equally. And they shouldn’t be. When developing aptamers to protein targets the ‘how’ is just as important as the ‘what’. The ‘what’ is what…
Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…
Speed your small molecule detection and analysis with Optimer. Rapid development, rapid assays, rapid results. Download this datapack to learn how: success in discovery for small molecule ligand is increased…
As SARS-CoV-2 continues to mutate we demonstrate the performance of
Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…
SARS-CoV-2 was first identified in November 2019 in Wuhan, China. Spreading quickly across the globe, COVID-19, the disease caused by SARS_CoV-2, was announced as a pandemic just four months…
